Drugs / Oleoylethanolamide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07503782 | Aug 2026 → Mar 2031 expected | alcohol-related disorders | Medical University of South Carolina | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04614233 | Apr 2021 → Oct 2024 | morbid obesity | Yale University | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oleoylethanolamide | “The primary objective is to test if fat intake moderates the ability of oleoylethanolamide (OEA) to improve weight loss maintenance after the LEARN® weight loss program.” NCT04614233 ↗ |
| Known as | OEA | “The primary objective is to test if fat intake moderates the ability of oleoylethanolamide (OEA) to improve weight loss maintenance after the LEARN® weight loss program.” NCT04614233 ↗1“250 mg Oleoylethanolamide (OEA) administered daily for 6 weeks.” NCT07503782 ↗ |
| Action | Activate | “peroxisome proliferator-activated receptor-alpha (PPAR-α) agonist” NCT07503782 ↗ |
| Modality | Other / unclassified | “OEA is an endogenous lipid mediator and peroxisome proliferator-activated receptor-alpha (PPAR-α) agonist” NCT07503782 ↗ |
| Route | Oral | “Participants receive 300mg TRIPTI a day (providing 250 mg/day oleoylethanolamide [OEA]) orally for 6 weeks.” NCT07503782 ↗ |